Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
15-Dec-2022
Kazia pre-clinical collaboration with QIMR
13-Dec-2022
Kazia receives Nasdaq minimum bid notice
1-Dec-2022
EVT801 preclinical data published
16-Nov-2022
Kazia AGM results
16-Nov-2022
AGM materials
14-Nov-2022
Change in substantial holding
9-Nov-2022
Kazia presents to Bell Potter Healthcare Conference
9-Nov-2022
Kazia to present to SNO
7-Nov-2022
Change in substantial holding
4-Nov-2022
Cleansing notice
1
2
3
4
5
6
7
8
9
10
Next
